Peroxisome Proliferator-activated Receptor gamma  Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo*

Xiaohua Xin, Suya Yang, Joe Kowalski, and Mary E. GerritsenDagger

From the Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Peroxisome proliferator-activated receptor gamma  (PPARgamma ) is a nuclear receptor that functions as a transcription factor to mediate ligand-dependent transcriptional regulation. Activation of PPARgamma by the naturally occurring ligand, 15-deoxy-Delta 12,14-prostaglandin J2 (15d-PGJ2), or members of a new class of oral antidiabetic agents, e.g. BRL49653 and ciglitizone, has been linked to adipocyte differentiation, regulation of glucose homeostasis, inhibition of macrophage and monocyte activation, and inhibition of tumor cell proliferation. Here we report that human umbilical vein endothelial cells (HUVEC) express PPARgamma mRNA and protein. Activation of PPARgamma by the specific ligands 15d-PGJ2, BRL49653, or ciglitizone, dose dependently suppresses HUVEC differentiation into tube-like structures in three-dimensional collagen gels. In contrast, specific PPARalpha and -beta ligands do not affect tube formation although mRNA for these receptors are expressed in HUVEC. PPARgamma ligands also inhibit the proliferative response of HUVEC to exogenous growth factors. Treatment of HUVEC with 15d-PGJ2 also reduced mRNA levels of vascular endothelial cell growth factor receptors 1 (Flt-1) and 2 (Flk/KDR) and urokinase plasminogen activator and increased plasminogen activator inhibitor-1 (PAI-1) mRNA. Finally, administration of 15d-PGJ2 inhibited vascular endothelial cell growth factor-induced angiogenesis in the rat cornea. These observations demonstrate that PPARgamma ligands are potent inhibitors of angiogenesis in vitro and in vivo, and suggest that PPARgamma may be an important molecular target for the development of small-molecule inhibitors of angiogenesis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Angiogenesis, the formation of new blood vessels, is not only critically involved in a number of normal physiological processes such as embryonic development, ovulation, and wound healing, but is also a critical step in many pathological conditions including solid tumor growth, diabetic retinopathy, and age-related macular degeneration (1). The complex steps involved in new vessel formation have been well characterized in recent years and involve the degradation of the basement membrane by cellular proteases, the penetration and migration of endothelial cells into the extracellular matrix, endothelial proliferation, and the resultant formation of patent, interconnected vascular networks (2, 3). It is now well established that the progression of solid tumor growth and metastasis is dependent on angiogenesis, with the resultant global effort by many laboratories to identify new angiostatic therapies for the treatment of cancer.

Peroxisome proliferator-activated receptors (PPARs)1 are members of the steroid receptor superfamily and, as such, are ligand-activated transcription factors (4, 5). Three subtypes of PPAR, alpha , beta  (also known as delta  or NUCI), and gamma  have been identified and cloned. Like other members of this superfamily, PPARs mediate transcriptional regulation by their central DNA binding domain that recognizes response elements in the promoters of specific target genes (6, 7). Activation of PPARgamma has been linked to adipocyte differentiation and regulation of glucose homeostasis in rodents and humans (8). Recent evidence also shows that the natural receptor ligand for PPARgamma , 15d-PGJ2 (9, 10), and synthetic antidiabetic thiazolidinedione drugs (e.g. BRL49653 and ciglitizone), inhibit macrophage and monocyte activation (11, 12) and suppress tumor cell growth (14-16). PPARgamma can heterodimerize with at least one other member of the steroid receptor superfamily, retinoid acid receptor (RXR) (6, 17). Specific ligands for the PPARgamma and RXR have been shown to act synergistically to induce terminal differentiation of human liposarcoma cells (18) in vitro and to enhance insulin sensitivity in diabetic animals (19). Activation of PPARalpha has been demonstrated to mediate lipid catabolism. Treatment of animals with PPARalpha activators results in the proliferation of peroxisomes and the induction of hepatic genes involved in the beta -oxidation of fatty acids (20). Mice that lack functional PPARalpha accumulate lipid droplets in their livers (21). Several selective PPARalpha activators have been described including WY 14643 and clofibrate (22). Inhibition of human aortic smooth muscle cell activation by PPARalpha ligands has also been reported recently (13). Although PPARbeta has been found to be ubiquitously expressed, specific functions for this receptor are not known at the present time.

In this study we report on the potent and novel inhibitory activity of PPARgamma ligands on HUVEC differentiation into tube-like structures and proliferation in vitro, and the inhibition of VEGF elicited angiogenesis in vivo. These studies demonstrate that PPARgamma is an important molecular target for the development of small molecule inhibitors of angiogenesis, which may be useful therapeutic agents in the treatment of cancer and other vasculoproliferative disorders.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Materials-- PGA1, PGA2, PGB1, PGB2, PGD1, PGD2, PGE1, PGE2, ciglitizone, WY 14643, clofibrate, and 15d-PGJ2 were from Cayman Chemical (Ann Arbor, MI). BRL49653 was kindly synthesized at Genentech by Dr. Jim Marsters (South San Francisco, CA). HUVEC were purchased from Clonetics (San Diego, CA) and maintained in Clonetics EGM medium supplemented with 10% fetal bovine serum (FBS) and endothelial cell growth supplements provided by the company. Type I rat tail collagen and recombinant basic fibroblast growth factor (bFGF) were purchased from Collaborative Research (Becton Dickinson Labware, Bedford, MA). Recombinant VEGF was from Genentech. 10× medium 199 (M199) and PMA were purchased from Sigma. FBS was from Hyclone (Logan, Utah). ITS (insulin, transferrin, and selenium A), trypsin, and versene were from Life Technologies, Inc. The mouse monoclonal antibody to PPARgamma (E-8, SC-7273) and goat polyclonal antibodies to PPARalpha (N-19, SC-1985) and PPARbeta (C-20, SC-1983) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Magnetic protein A beads (Dynabeads) were from Dynal (Lake Success, NY).

Endothelial Tube Assay-- Collagen gels were formed by mixing together ice-cold gelation solution (10× M199, H2O, 0.53 M NaHCO3, 200 mM L-glutamine, type I collagen, 0.1 M NaOH, 100:27.2:50:10:750:62.5 by volume) and cells in 1× basal medium (see below) at a concentration of 3 × 106 cells/ml at a ratio of 4 volumes gelation solution:1 volume of cells. After gelation at 37 °C for 30 min, the gels were overlaid with 1× basal medium consisting of M199 supplemented with 1% FBS, 1× ITS, 2 mM L-glutamine, 50 µg/ml ascorbic acid, 26.5 mM NaHCO3, 100 units/ml penicillin, and 100 units/ml streptomycin supplemented with 40 ng/ml bFGF, 40 ng/ml VEGF, and 80 nM PMA. All drugs were added to the 1× basal medium immediately after gelation. To quantitate tube formation, the number of tubes per high power (20X) field was determined at 48 h after addition of the basal medium. A tube was defined as an elongated structure comprised of one or more endothelial cells that exceeded 100 µm in length (long axis). Five independent fields separated by 100 µm optical sections were assessed for each well, and the average number of tubes/20X field determined. Cytoxicity was assessed using cell proliferation kit II from Boehringer Mannheim.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Assays-- Synthesis of complementary DNA (cDNA) was performed using 6 µg of total RNA extracted from human liver (positive control) or HUVEC cultured on three-dimensional collagen gels for 24 h by random primer according to the manufacturer's instructions (Stratagene Co., San Diego, CA). Subsequent amplifications of the partial cDNA encoding PPARalpha , beta , and gamma  were performed using different amounts of reverse transcribed mixture (4 µl for liver alpha , beta , and gamma  and 5 µl for HUVEC alpha  and beta  and 6 µl for HUVEC gamma ) as templates with specific oligonucleotide primers as follows: PPARalpha sense 5'-CCAGTATTTAGGACGCGGTCC-3' and antisense 5'-AAGTTCTTCAAGTAGGCCTGCG-3'; PPARbeta sense 5'-AACTGCAGATGGGCTGTGAC-3' and antisense 5'-GTCTCGATGTCGTGGATCAC-3' and PPARgamma sense 5'-TCTCTCCGTAATGGAAGACC-3' and antisense 5'-GCATTATGAGACATCCCCAC-3'. The expected sizes of PCR products for PPAR alpha , beta , and gamma  were 492, 484, and 474 base pairs, respectively. Negative controls for reverse transcription and PCR amplifications were included. The PCR mixtures were subjected to 35 cycles of amplification by denaturation (30 s at 94 °C), hybridization (30 s at 55 °C), and elongation (45 s at 55 °C). The PCR products were analyzed by 1.5% agarose gel electrophoresis with ethidium bromide.

Real Time RT-PCR (Taqman) Assay-- This technique has been used to quantitatively monitor mRNA expression and has been described in detail previously (26, 27). Total RNA was extracted from HUVEC cultured in three-dimensional collagen gels or on collagen-coated flasks for various times in 1× basal medium consisting of M199 supplemented with 1% FBS, 1× ITS, 2 mM L-glutamine, 50 µg/ml ascorbic acid, 26.5 mM NaHCO3, 100 units/ml penicillin, and 100 units/ml streptomycin supplemented with 40 ng/ml bFGF, 40 ng/ml VEGF, and 80 nM PMA. A gene-specific PCR oligonucleotide primer pair and an oligonucleotide probe labeled with a reporter fluorescent dye at the 5'-end and a quencher fluorescent dye at the 3'-end were designed using the Oligo 4.0 software (National Bioscience, Plymouth, MN) following guidelines suggested in the Taqman Model 7700 sequence detection instrument manual (PE Applied Biosystem). The primers and probes used were as follows: human PPARalpha gene forward primer 5'-GGACGTGCTTCCTGCTTCAT-3', reverse primer 5'-CACCATCGCGACCAGATG-3', and probe 5'-TTGGAGCTCGGCGCACAACCA-3'; human PPARbeta gene forward primer 5'-TGACCTGCGGCAACTGG-3', reverse primer 5'-TTCGGTCTTCTTGATCCGCT-3', and probe 5'-CACCGAGCACGCCCAGATGATG-3'; human PPARgamma gene forward primer 5'-GCCAAGCTGCTCCAGAAAAT-3', reverse primer 5'-TGATCACCTGCAGTAGCTGCA-3', and probe 5'-ACAGACCTCAGACAGATTGTCACGGAACAC-3'; human Flk/KDR gene forward primer 5'-CACCACTCAAACGCTGACATGTA-3', reverse primer 5'-CCAACTGCCAATACCAGTGGA-3', and probe 5'-TGCCATTCCTCCCCCGCATC-3'; human Flt-1 gene forward primer 5'-ACCCAGATGAAGTTCCTTTGGA-3', reverse primer 5'-CCCAGTTTAGTCTCTCCCGG-3', and probe 5'-CCTTATGATGCCAGCAAGTGGGAGTTTG-3'; human urokinase-type plasminogen activator (uPA) gene forward primer 5'-ACGCTTGCTCACCAGAATGA-3', reverse primer 5'-GCGCACACCTGCCCTC-3', and probe 5'-ATTGCCTTGCTGAAGATCCGTTCCAA-3'; human PAI-1 gene forward primer 5'-TCGTCCAGCGGGATCTGA-3', reverse primer 5'-GTGCTCCGGAACAGCCTG-3', and probe 5'-CCAGGGCTTCATGCCCCACTTCT-3'; human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene forward 5'-GAAGGTGAAGGTCGGAGTC-3', reverse 5'-GAAGATGGTGATGGGATTTC-3', and probe 5'-CAAGCTTCCCGTTCTCAGCC-3'. Total RNA (100 ng) was added to a 50-µl RT-PCR reaction mixture according to the manufacturer's protocol (Roche Molecular Systems, Inc., Branchburg, NJ). The thermal cycling conditions included 1 cycle at 48 °C for 30 min, 1 cycle at 95 °C for 10 min, 40 cycles at 95 °C for 15 s, at 60 °C for 1 min, and finally hold at 25 °C for 2 min. Standard curves for expression of each gene were generated by serial dilution of the total RNA isolated from HUVEC. Expression of GAPDH gene was not significantly altered during the times (up to 48 h) of incubation with drugs and vehicle. Therefore, the relative mRNA expression of each gene was normalized to the level of GAPDH in the same RNA preparation.

Western Blot Assays-- Confluent HUVEC grown on type I collagen-coated flasks were washed once with ice-cold phosphate-buffered saline, then scraped and pelleted by centrifugation. Pellets were lysed in ice-cold lysis buffer (20 mM Tris/HCl, 150 mM NaCl, 2 mM EDTA, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 40 units/ml aprotinin, 15 µg/ml leupeptin, 0.36 mM 1,10-phenanthroline, 1% Nonidet P-40, and 1% Triton X-100, pH 7.5). An aliquot equivalent to 100 µg of protein was incubated for 16 h at 4 °C with 20 ng of anti-PPAR antibody in a total volume of 500 µl. Protein-A agarose beads (50 µl) were then added, and the mixture incubated for 2 h at 4 °C. The beads were washed three times with 500 µl of lysis buffer, and the proteins remaining on the beads were solubilized by heating at 100 °C for 5 min in 2× SDS sample buffer. The precipitated complexes were then analyzed by Western blotting. Proteins were visualized using the ECL chemiluminescence kit (Amersham Pharmacia Biotech).

Proliferation Assay-- HUVEC were seeded on collagen-coated 96-well plates at 6,000 cells/cm2 in Clonetics EGM containing endothelial cell growth supplements and 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin, and 100 units/ml streptomycin and allowed to attach for 4 h. Medium was then replaced with 1× basal medium consisting of M199 supplemented with 1% FBS, 1× ITS, 2 mM L-glutamine, 50 µg/ml ascorbic acid, 26.5 mM NaHCO3, 100 units/ml penicillin, and 100 units/ml streptomycin supplemented with 40 ng/ml bFGF, 40 ng/ml VEGF, and 80 nM PMA. Cells were cultured in the above medium in the presence of drugs or vehicle for 4 h. 5 µl (100 µM) of 5'-bromo-2'-deoxyuridine (BrdUrd) was added in a final volume of 100 µl/well, and cells were incubated for another 20 h. BrdUrd incorporation was evaluated by an enzyme-linked immunosorbent assay kit from Boehringer Mannheim.

Corneal Angiogenesis Assay-- A 1.5-mm incision was made approximately 1 mm from the center of the cornea of isoflurane-ketamine (60-80 mg/kg) xylazine (10-15 mg/kg) anesthetized Sprague-Dawley rats. Using a curved spatula, the incision was bluntly dissected through the stroma toward the outer canthus of the eye. A hydron pellet (2 × 20 mm) containing VEGF (200 ng), sucralfrate (100 ng) with or without (control) 15d-PGJ2 (10 µg/pellet) was inserted into the base of the pocket. After surgery the eyes were coated with gentamicin ointment. Animals were observed at 24-48 h for the occurrence of nonspecific inflammation and then daily thereafter. At day 6, the animals were euthanized and injected with fluorescein isothiocyanate-dextran to allow for visualization of the vasculature. Corneal whole mounts were made of the enucleated eyes and analyzed for neovascular area using computer-assisted image analysis (Image Pro-Plus 2.0, Silver Spring, MD).

Statistics-- Data are expressed as the mean ± S.E. Statistic analysis was performed using one-way analysis of variance (INSTAT, Graph Pad Software, Sorrento Valley, CA). Multiple comparisons against the control were analyzed using Bonferroni modification of Student's t test to determine differences between groups. A p value < 0.05 was accepted as significant.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Endothelial Tube Formation in Three-dimensional Collagen Gels-- In this study we used a model of in vitro angiogenesis initially described by Davis et al. (23). In this model, endothelial cells suspended in three-dimensional collagen lattices comprised of type I collagen in the presence of VEGF, bFGF, and PMA undergo rapid morphogenesis. Numerous vacuoles are observed in the majority of endothelial cells within 4 h; the formation of tube-like structures can be observed at 24 h, and an interconnected network of tube-like structures is observed (Fig. 1A) at 48 h. Inhibitors of mRNA synthesis (actinomycin D) and protein synthesis (cycloheximide) completely blocked the formation of tube-like structures (data not shown), demonstrating the requirement for new mRNA and protein synthesis.


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of eicosanoid derivatives on HUVEC tube formation in three-dimensional collagen gels. Panel A, representative photomicrograph documenting the formation of network of tube-like structures containing lumens in HUVEC grown in three-dimensional collagen gels for 48 h in the presence of 40 ng/ml VEGF, 40 ng/ml bFGF, and 80 nM PMA; panel B, inhibitory effects of 15d-PGJ2 on tube formation. HUVEC were grown in three-dimensional collagen gels in the presence of VEGF, bFGF, and PMA as well as 10 µM 15d-PGJ2 for 48 h. Note that most cells in the gel remain rounded and devoid of vacuoles or lumen-like structures. Parallel experiments using the vehicle and growth factors were similar to panel A. Panel C, effects of different eicosanoids on tube formation of HUVEC in three-dimensional collagen gels. Drugs were tested at 1, 10, and 100 µM. Data are expressed as percent inhibition compared with controls incubated with growth factors and the vehicle and are shown as mean ± S.E. of n >=  3. *, significantly different from vehicle treated control (Bonferroni modified Student's t test for multiple comparisons).

Effects of Eicosanoids on Tube Formation by HUVEC-- It has recently been shown that a number of eicosanoid metabolites can serve as PPAR ligands (8-10, 22), and activation of PPARs has been linked to numerous functions in a number of cell types (8, 11-16). To determine whether PPARs could affect HUVEC differentiation, we investigated the effect of 15d-PGJ2, a naturally occurring endogenous ligand of PPARgamma on HUVEC tube formation. HUVEC were grown in three-dimensional collagen gels in medium containing VEGF, bFGF and PMA with addition of 15d-PGJ2 (10 µM) for 48 h and were analyzed for tube formation. As shown in Fig. 1B, 15d-PGJ2 markedly reduced HUVEC tube formation. The majority of cells in the gels remained rounded and devoid of vacuoles or lumen-like structures. Vehicle-treated control groups did not show any significant inhibitory effect (data not shown). We extended our observations to a variety of metabolites of 20:4 and 20:3 fatty acids for their ability to inhibit tube formation in three-dimensional collagen gels (Fig. 1C). PGJ2 and PGD2 and their derivatives/analogs demonstrated dose-dependent inhibition of tube formation over the concentration range of 1 to 100 µM. PGB1 and PGB2 possessed only weak inhibitory effects. In contrast, two prostanoids known to activate cell surface G-protein-coupled receptors, namely PGE1 and PGE2, had no significant effect over this concentration range. Among the tested drugs, 15d-PGJ2 was the most potent inhibitor of HUVEC tube formation. Data from parallel cytotoxicity assays indicated that none of the tested prostanoids exhibited significant toxicity over the time course (48 h) of the experiment (data not shown). Previous studies (24, 25) have demonstrated that PGD2 can spontaneously convert to PGJ2, and in the presence of serum or albumin, to 15d-PGJ2, a natural selective ligand for PPARgamma . Therefore, activation of PPARgamma may modulate endothelial morphogenesis.

PPARgamma Is Expressed in HUVEC-- RT-PCR was used to demonstrate the expression of all three PPAR (alpha , beta , and gamma ) mRNAs in HUVEC cultured in the three-dimensional collagen gels. In two independent experiments conducted with different HUVEC populations derived from different donors, the mRNA expression of three isoforms of PPAR were demonstrated (Fig. 2A). By using real time quantitative RT-PCR (Taqman) (26, 27), the relative mRNA expression levels of each isoform were determined to be PPARbeta  > PPARalpha  > PPARgamma (Fig. 2B). Preliminary observations also suggested that expression of PPARgamma mRNA was not altered in medium containing VEGF, bFGF and PMA at 4, 24 or 48 h of incubation with 15d-PGJ2 or vehicle in HUVEC cultured in three-dimensional collagen gels or on collagen-coated surfaces (data not shown). The expression of PPARgamma protein in HUVEC was confirmed by Western blot analysis (Fig. 2C), and PPARgamma protein levels were not significantly altered by the growth factor mixture when HUVEC were cultured on collagen-coated surfaces (Fig. 2C). Using commercially available antibodies, we were unable to demonstrate protein expression of PPARalpha and -beta in HUVEC (data not shown). The expression of PPARalpha mRNA in HUVEC has been previously reported (28); however, this study demonstrates for the first time the expression of PPARgamma mRNA and protein and PPARbeta mRNA by HUVEC.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of PPAR in HUVEC. A, RT-PCR analysis using specific primers for PPARalpha , -beta , or -gamma as described under "Experimental Procedures." Specific cDNA were synthesized from human liver RNA (positive control) and from HUVEC RNA using random primer in the presence of 50 units of Moloney murine leukemia virus reverse transcriptase. PCR products were resolved on a 1.5% agarose gel. The DNA ladder was included as a marker to indicate the sizes of the PCR products of PPARalpha (lanes 1 and 4), -beta (lanes 2 and 5), and -gamma (lanes 3 and 6). B, quantitative analysis of mRNA expression of PPARs in HUVEC by real time RT-PCR (Taqman). Total RNA (100 ng) were extracted from HUVEC grown in three-dimensional collagen gels in medium containing VEGF, bFGF and PMA. The relative expression of PPAR isoforms were normalized to GAPDH levels measured in the same RNA preparation. Data shown are from three independent experiments analyzed in duplicate and are expressed as mean ± S.E. C, Western blot analysis of PPARgamma expression in HUVEC. Tissue extract from mouse adipose tissue (20 µg of protein, positive control) or HUVEC cell lysates (100 µg of protein) prepared from cells cultured on collagen-coated surfaces in 1× basal medium without (lane 1) or containing (lane 2) VEGF, bFGF, and PMA for 24 h were immunoprecipitated by PPARgamma monoclonal antibody. Following SDS-polyacrylamide gel electrophoresis and transfer to nitrocellulose, the proteins were immunoblotted with the same PPARgamma monoclonal antibody. Similar results were obtained from two independent experiments with different HUVEC cultures.

PPARgamma Mediates the Inhibitory Effect on HUVEC Tube Formation and Proliferation-- To determine which PPAR isoform(s) mediated the inhibition of HUVEC tube formation, the effect of specific PPAR ligands was assessed. As shown in Fig. 3A, treatment of HUVEC with the specific PPARgamma ligands, 15d-PGJ2, BRL49653, and ciglitizone, dose dependently inhibited tube formation with half-maximal inhibition concentrations (IC50) of 2.8, 6.2, and 2.7 µM, respectively. In contrast, the selective agonists for PPARalpha (WY 14643 and clofibrate) and PPARbeta (erucic acid) (29) did not significantly inhibit tube formation (Fig. 3B). These observations demonstrated that activation of PPARgamma results in inhibition of endothelial cell differentiation into tube-like structures in vitro. We further investigated whether PPARgamma ligands also regulate the proliferative response of HUVEC to growth factors. BrdUrd incorporation assays were performed to detect proliferation of HUVEC cultured on type I collagen-coated surface in medium containing VEGF, bFGF, and PMA in the presence of vehicle or PPARgamma ligands. As shown in Fig. 3C, 15d-PGJ2 and BRL49653 dose dependently inhibited HUVEC proliferation with IC50 of 2.4 and 15.7 µM, respectively. In contrast, PGE1 and PGE2 did not affect HUVEC proliferation (data not shown). These results demonstrate that PPARgamma ligands also repress growth factor-induced HUVEC proliferation in vitro.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of PPAR ligands on HUVEC tube formation and proliferation. HUVEC were cultured in three-dimensional collagen gels in medium containing VEGF, bFGF, and PMA for 48 h with addition of either PPAR ligands or vehicle (A and B). A, dose-dependent inhibition of HUVEC tube formation by PPARgamma ligands, 15d-PGJ2, BRL49653, and ciglitizone (Cgt); B, selective ligands of PPARalpha (WY 14643, 100 µM and clofibrate, 100 µM) and PPARbeta (erucic acid, 200 µM) do not inhibit tube formation; C, PPARgamma activation inhibits HUVEC proliferation. HUVEC cultured on type I collagen-coated surfaces in medium containing VEGF, bFGF, and PMA were treated with various concentrations of 15d-PGJ2 or BRL49653. Cell proliferation was monitored as BrdUrd incorporation. Data in A, B, and C are the mean ± S.E. from three to four independent experiments. Data are expressed as percent inhibition (A and C) or percent of control (B) compared with vehicle treated groups in the presence of growth factors.

15d-PGJ2 Regulates Gene Expression Events Associated with Angiogenesis-- Flk/KDR and Flt-1 are two structurally related endothelial cell tyrosine kinase receptors for VEGF. The importance of these two receptors during angiogenesis has been clearly demonstrated by the findings that KDR functions as a transducer to signal endothelial cell proliferation and differentiation and that Flt-1 is a critical survival factor involved in endothelial cell morphogenesis (30-32). We examined whether activation of PPARgamma alters Flt-1 and KDR gene expression using real time quantitative RT-PCR. Both KDR and Flt-1 mRNA were up-regulated by the mixture of growth factors in HUVEC grown in three-dimensional collagen gels (Fig. 4, A and B, open bars). 15d-PGJ2 inhibited the induction of both VEGF receptor mRNA in HUVEC cultured in three-dimensional collagen gels (Fig. 4, A and B, hatched bars). Similar data were obtained when HUVEC were grown on type I collagen-coated surface with growth factor stimulation (not shown). It is also well known that the production of proteases (e.g. plasminogen activators) and their inhibitors (e.g. plasminogen activator inhibitor I, PAI-1) is correlated with endothelial cell degradation of extracellular matrix and migration, the two critical steps of the angiogenic processes (33). We analyzed the effects of 15d-PGJ2 on gene expression of uPA and PAI-1 in three-dimensional collagen gels. Treatment of HUVEC with 15d-PGJ2 reduced uPA mRNA at 4 h and increased PAI-1 gene expression at 24 h, respectively (Fig. 4, C and D, hatched bars). Taken together, these observations indicate some possible molecular mechanisms by which PPARgamma ligands mediate inhibition of angiogenesis.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Regulation of angiogenesis associated gene expression by 15d-PGJ2. Total RNA (100 ng) were isolated from HUVEC grown in three-dimensional collagen gels for the indicated times in medium containing VEGF, bFGF, and PMA in the presence of 10 µM 15d-PGJ2 (hatched bars) or vehicle (open bars). The mRNA levels of the indicated genes were determined by real time quantitative RT-PCR (Taqman) analysis. The relative expression levels of each gene were normalized to the levels of GAPDH measured in the same RNA preparation. #, significantly different from control groups at 4 h; *, significantly different from time-matched control groups. Data are shown as means ± S.E. from three to five independent experiments and were analyzed by one-way analysis of variance.

15d-PGJ2 Demonstrates Anti-angiogenic Activity in Vivo-- To determine the potential anti-angiogenic effect of PPARgamma ligand 15d-PGJ2 in vivo, hydron pellets containing 200 ng of recombinant VEGF with or without 10 µg of 15d-PGJ2 were implanted into the corneas of Sprague-Dawley rats. Summary data from the experiment show that pellets containing the combination of 15d-PGJ2 and VEGF demonstrated a significant reduction in vessel area compared with the VEGF only positive controls (Fig. 5, A, B, and C). Results from this experiment were repeated in a second independent experiment. These in vivo data strongly support our in vitro observations that activation of PPARgamma results in marked inhibition of angiogenesis.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 5.   Anti-angiogenic effect of 15d-PGJ2 in vivo. Representative flatmount photographs of rat corneas 5 days after implantation of hydron pellets containing 200 ng/pellet VEGF (A) or 200 ng/pellet VEGF and 10 µg/ml 15d-PGJ2 (B). Bar graph (C) shows the summary data of the angiogenic response induced by 200 ng/pellet VEGF alone or 200 ng/pellet VEGF and 10 µg/ml 15d-PGJ2. The area of new vessels was assessed on day 6 postimplantation. Data are expressed as mean ± S.E. *, significantly different from control (Ctr); +, significantly different from VEGF alone groups (Mann-Whitney test for nonparametric values).

Recent evidence has demonstrated that PPARgamma is highly expressed in most colon cancer cells and breast cancer cells (14, 16). Activation of the PPARgamma resulted in growth arrest and induction of differentiation of cancer cells and reduction of tumor cell growth rate, suggesting potential implications of PPARgamma as a target for treatment of human cancers. In this study we have documented, for the first time, the expression of PPARgamma in human endothelial cells. Activation of PPARgamma with either naturally occurring ligand or synthetic selective ligands results in potent inhibition of endothelial differentiation into tube-like structures and proliferation in vitro and suppression of VEGF-induced angiogenesis in vivo. PPARgamma activation also inhibits the expression of at least three important genes in the angiogenic process, the VEGF receptors Flk/KDR, Flt-1, and the protease uPA. This study thus provides a new insight into the mechanism of PPARgamma ligands as inhibitors of solid tumor growth and suggests that such drugs may also provide novel means to control other angiogenic disorders.

    ACKNOWLEDGEMENTS

We thank the DNA synthesis group at Genentech for oligonucleotides and real time RT-PCR probes.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Cardiovascular Research, MS 42, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Tel.: 650-225-6870; Fax: 650-225-6327; E-mail: meg{at}gene.com.

    ABBREVIATIONS

The abbreviations used are: PPARs, peroxisome proliferator-activated receptors; HUVEC, human umbilical vein endothelial cells; 15d-PGJ2, 15-deoxy-Delta 12,14-prostaglandin J2; RXR, retinoid acid receptor; VEGF, vascular endothelial growth factor; PMA, phorbol myristate acetate; RT-PCR, reverse transcription-polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; BrdUrd, 5'-bromo-2'-deoxyuridine; FBS, fetal bovine serum; bFGF, basic fibroblast growth factor; ITS, insulin, transferrin, and selenium A; uPA, urokinase-type plasminogen activator.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
  1. Folkman, J. (1995) Nat. Med. 1, 27-31[Medline] [Order article via Infotrieve]
  2. Folkman, J. (1986) Cancer Res. 46, 467-473[Medline] [Order article via Infotrieve]
  3. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991) Cell 64, 327-336[Medline] [Order article via Infotrieve]
  4. Issemann, I., and Green, S. (1990) Nature 347, 645-650[CrossRef][Medline] [Order article via Infotrieve]
  5. Schoonjans, K., Martin, G., Staels, B., and Auwerx, J. (1997) Curr. Opin. Lipidol. 8, 159-166[Medline] [Order article via Infotrieve]
  6. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. (1992) Nature 358, 771-774[CrossRef][Medline] [Order article via Infotrieve]
  7. Palmer, C. N. A., Hsu, M. H., Griffin, K. J., and Johnson, E. F. (1995) J. Biol. Chem. 270, 16114-16121[Abstract/Free Full Text]
  8. Spiegelman, B. M. (1998) Diabetes 47, 507-514[Abstract]
  9. Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., and Lehmann, J. M. (1995) Cell 83, 813-819[Medline] [Order article via Infotrieve]
  10. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) Cell 83, 803-812[Medline] [Order article via Infotrieve]
  11. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) Nature 391, 79-82[CrossRef][Medline] [Order article via Infotrieve]
  12. Jiang, C., Ting, A. T., and Seed, B. (1998) Nature 391, 82-86[CrossRef][Medline] [Order article via Infotrieve]
  13. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., A, F., Chinetti, G., Fruchart, J., Najib, J., Maclouf, J., and Tedgui, A. (1998) Nature 393, 790-793[CrossRef][Medline] [Order article via Infotrieve]
  14. Elstner, E., Muller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8806-8811[Abstract/Free Full Text]
  15. Kubota, T., Koshizuka, K., Williamson, E., Asou, H., Said, J., Holden, S., Miyoshi, I., and Koeffler, H. P. (1998) Cancer Res. 58, 3344-3352[Abstract]
  16. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. A. (1998) Nat. Med. 4, 1046-1052[CrossRef][Medline] [Order article via Infotrieve]
  17. Schulman, I. G., Shao, G., and Heyman, R. A. (1998) Mol. Cell. Biol. 18, 3483-3494[Abstract/Free Full Text]
  18. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 237-241[Abstract/Free Full Text]
  19. Mukherjee, R., Davies, P. J. A., Crombie, D. J., Bischoff, E. D., Cesario, R. M., Jow, L., Hamam, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., Paterniti, J. R., Jr., and Heyman, R. A. (1997) Nature 386, 407-410[CrossRef][Medline] [Order article via Infotrieve]
  20. Issemann, I., and Green, S. (1990) Nature 347, 645-650[CrossRef][Medline] [Order article via Infotrieve]
  21. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995) Mol. Cell. Biol. 15, 3012-3022[Abstract]
  22. Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317[Abstract/Free Full Text]
  23. Davis, G. E., and Camarillo, C. W. (1996) Exp. Cell Res. 224, 39-51[CrossRef][Medline] [Order article via Infotrieve]
  24. Fitzpatrick, F. A., and Wynalda, M. A. (1983) J. Biol. Chem. 258, 11713-11718[Abstract/Free Full Text]
  25. Giles, H., and Leff, P. (1988) Prostaglandins 35, 277-300[CrossRef][Medline] [Order article via Infotrieve]
  26. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. (1996) Genome Methods 6, 986-994
  27. Gerber, H., Condorelli, F., Park, J., and Ferrara, N. (1997) J. Biol. Chem. 272, 23659-23667[Abstract/Free Full Text]
  28. Inoue, I., Shino, K., Noji, S., Awata, T., and Katayama, S. (1998) Biochem. Biophys. Res. Commun. 246, 370-374[CrossRef][Medline] [Order article via Infotrieve]
  29. Johnson, T. E., Holloway, M. K., Vogel, R., Rutledge, S. J., Perkins, J. J., Rodan, G. A., and Schmidt, A. (1997) J. Steroid Biochem. Mol. Biol. 63, 1-8[CrossRef][Medline] [Order article via Infotrieve]
  30. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. (1995) Nature 376, 66-70[CrossRef][Medline] [Order article via Infotrieve]
  31. Ferrara, N., and Davis-Smyth, T. (1997) Endocr. Rev. 18, 4-25[Abstract/Free Full Text]
  32. Ilan, N., Mahooti, S., and Madri, J. A. (1998) J. Cell Sci. 111, 3621-3631[Abstract/Free Full Text]
  33. Chapman, H. A. (1997) Curr. Opin. Cell Biol. 9, 714-724[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.